OS (A) and EFS (B) by exposure to new haplotype. The median survival was 552 days (95% CI 376–2950+) in the group transplanted with a second graft that did not harbor a new mismatched haplotype, while it was not reached in the group whose allograft contained a new mismatched haplotype (HR 0.36, 95% CI 0.14 – 0.9; p=0.02). The median event free survival was also longer in the group who received an allograft containing a new mismatched haplotype (NR versus 401 days, HR 0.50, 95% CI .22–1.14, p=0.09)